Vaccine formulations and schedules
| Vaccine name . | Antigen . | Adjuvant . | Schedule . |
|---|---|---|---|
| gE/AS01B | VZV gE (50 µg) | AS01B liposome-based adjuvant: 50 µg monophosphoryl lipid A (MPL) and 50 µg Quillaja saponaria Molina 21 (QS21) | 3 doses at months 0, 1, and 3; or 2 doses at months 1 and 3 (1 dose of saline at month 0) |
| gE/AS01E | VZV gE (50 µg) | AS01E liposome-based adjuvant: 25 µg monophosphoryl lipid A (MPL) and 25 µg Quillaja saponaria Molina 21 (QS21) | 3 doses at months 0, 1, and 3 |
| Saline (placebo) | None | None | 3 doses at months 0, 1, and 3 |
| Vaccine name . | Antigen . | Adjuvant . | Schedule . |
|---|---|---|---|
| gE/AS01B | VZV gE (50 µg) | AS01B liposome-based adjuvant: 50 µg monophosphoryl lipid A (MPL) and 50 µg Quillaja saponaria Molina 21 (QS21) | 3 doses at months 0, 1, and 3; or 2 doses at months 1 and 3 (1 dose of saline at month 0) |
| gE/AS01E | VZV gE (50 µg) | AS01E liposome-based adjuvant: 25 µg monophosphoryl lipid A (MPL) and 25 µg Quillaja saponaria Molina 21 (QS21) | 3 doses at months 0, 1, and 3 |
| Saline (placebo) | None | None | 3 doses at months 0, 1, and 3 |
AS, adjuvant system; gE, glycoprotein E; VZV, varicella-zoster virus.